Xgeva

DRUG3 trials

Sponsors

Cancer Trials Ireland, Qilu Pharmaceutical Co., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd.

Conditions

Bone MetastasesCastration-resistant Prostate CancerMetastatic Cancer

Phase 2

Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

TerminatedNCT03869762

Cancer Trials IrelandBone Metastases, Castration-resistant Prostate Cancer, Metastatic Cancer

Start: 2019-01-09End: 2019-01-12Updated: 2024-09-25

Phase 3

To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Qilu Pharmaceutical Co., Ltd.Bone Metastases

Start: 2019-04-26End: 2022-06-10Target: 700Updated: 2020-09-22

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

CompletedNCT04812509

Mabwell (Shanghai) Bioscience Co., Ltd.Bone Metastases

Start: 2020-03-20End: 2022-01-28Updated: 2023-02-24

Related Papers

Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: A subgroup analysis of a randomized, double-blinded phase III study.

2025-06-01

Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases

JAMA Oncology2024-02-086 citations

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial

BioDrugs2023-02-2111 citations

A multicenter, randomized, double-blind, phase III trial comparing denosumab biosimilar QL1206 and denosumab in patients with bone metastases from solid tumors.

Journal of Clinical Oncology2022-06-01